| Literature DB >> 24238215 |
Laurenzia Ferraris1, Laura Milazzo, Davide Ricaboni, Cristina Mazzali, Giovanna Orlando, Giuliano Rizzardini, Marco Cicardi, Ferdinando Raimondi, Loredana Tocalli, Alessandro Cialfi, Paolo Vanelli, Massimo Galli, Carlo Antona, Spinello Antinori.
Abstract
BACKGROUND: This study aimed to provide a contemporary picture of the epidemiologic, clinical, microbiologic characteristics and in-hospital outcome of infective endocarditis (IE) observed in a single center in Italy.Entities:
Mesh:
Year: 2013 PMID: 24238215 PMCID: PMC4225612 DOI: 10.1186/1471-2334-13-545
Source DB: PubMed Journal: BMC Infect Dis ISSN: 1471-2334 Impact factor: 3.090
General characteristics of 166 patients with infective endocarditis (IE)
| | |||||
|---|---|---|---|---|---|
| 57 [43–72] | 53 [42–71] | 66 [50–75] | 0.01 | ||
| 104 (63%) | 72 (65%) | 32 (58%) | 0.4 | ||
| | |||||
| | < 7 days | 69 (37%) | 41 (35%) | 28 (39%) | |
| | >7 and ≤21 days | 42 (22%) | 25 (21%) | 17 (24%) | |
| | > 21 days | 55 (29%) | 34 (29%) | 21 (30%) | 1 |
| | NA | 23 (12%) | 18 (15%) | 5 (7%) | |
| | |||||
| | Cancer | 14 (7%) | 13 (11%) | 1 (1%) | 0.01 |
| | Hypertension | 39 (21%) | 21 (18%) | 18 (25%) | 0.2 |
| | Acute/chronic renal failure | 17 (9%) | 6 (5%) | 11 (15%) | 0.02 |
| | Ischemic cardiopathy | 21 (11%) | 9 (8%) | 12 (17%) | 0.05 |
| | Diabetes mellitus | 29 (15%) | 17 (14%) | 12 (17%) | 0.6 |
| | COPD | 9 (5%) | 4 (3%) | 5 (7%) | 0.2 |
| | CLD | 55 (29%) | 41 (35%) | 14 (20%) | 0.03 |
| | HIV infection | 35 (19%) | 27 (23%) | 8 (11%) | 0.05 |
| | CD4 cells/μL [IQR] | 268 [145–353] | 248 [124–313] | 447 [348–1814] | 0.008 |
| | HIV-RNA cp/mL (n 22) | | | | |
| | <10000 | 14 (40%) | 8 (30%) | 6 (75%) | |
| | 10000-100000 | 5 (14%) | 4 (15%) | 1 (13%) | 0.11 |
| | >100000 | 4 (11%) | 4 (15%) | 0 | |
| | NA | 12 (34%) | 11 (41%) | 1 (13%) | |
| | HAART at IE | | | | |
| | No | 21 (60%) | 15 (56%) | 6 (75%) | 0.2 |
| | Yes | 14 (40%) | 12 (44%) | 2 (25%) | |
| Data are median [interquartile range] or numbers (%). | |||||
NA, Not available; COPD, Chronic obstructive pulmonary disease; CLD, Chronic liver disease; HAART, Highly active antiretroviral therapy.
Figure 1Incident cases of IE observed at the L. Sacco Hospital in the period 2003–2010: p = 0.067 according to Cochran-Armitage trend test.
Underlying disorders and predisposing conditions in patients with infective endocarditis (IE)
| | | |||
|---|---|---|---|---|
| Current IV drug use | 50 (26%) | 35 (30%) | 15 (21%) | 0.2 |
| Steroid therapy | 5 (3%) | 3 (3%) | 2 (3%) | 1 |
| Previous IE | 36 (19%) | 12 (10%) | 24 (34%) | <0.0001 |
| Health care associated IE* | 54 (29%) | 33 (28%) | 21 (30%) | 0.3 |
| Congenital heart disease | 6 (3%) | 6 (5%) | 0 | 0.09 |
| Rheumatic heart disease | 9 (5%) | 8 (7%) | 1 (1%) | 0.2 |
| Pacemaker | 11 (6%) | 2 (2%) | 9 (13%) | 0.003 |
| Data are median [interquartile range] or numbers (%). | ||||
*Health care associated IE: chronic IV access/hemodialysis: 7/189 (4%); invasive procedures before IE (dental, urological and gastrointestinal procedures): 7/189 (4%) hospitalized in an acute care hospital before IE 38/189 (20%); resident in a nursing home or in a long-term care facility 2/189 (1%).
Figure 2Microorganisms cultured according to the different type of IE.MSSA: Methicillin-sensitive Staphylococcus aureus; CoNS: Coagulase-negative Staphylococci; Methicillin-resistant staphilococci: MRSA (methicillin-resistant Staphylococcus aureus), methicillin-resistant Staphylococcus epidermidis. Streptococcus spp. includes: Viridans group Streptococci (overall 41.7%); S. bovis (overall 25%); other Streptococci (overall 33.3%).
Complications, treatment and outcome of IE episodes
| | | ||||
|---|---|---|---|---|---|
| Complications | | | | | |
| | Embolizations* | 83 (44%) | 56 (47%) | 27 (38%) | 0.4 |
| | Heart failure | 49 (26%) | 32 (27%) | 17 (24%) | 0.6 |
| | Arrhythmias | 40 (21%) | 28 (24%) | 12 (17%) | 0.3 |
| | Intracardiac abscess | 15 (9%) | 6 (5%) | 9 (15%) | 0.04 |
| | Renal failure | 12 (6%) | 6 (5%) | 6 (8%) | 0.4 |
| | Septic shock | 8 (4%) | 2 (2%) | 6 (8%) | 0.05 |
| Medical treatment | |||||
| | Monotherapy | 18 (10%) | 13 (11%) | 5 (7%) | 0.02 |
| | Dual therapy | 115 (62%) | 78 (68%) | 37 (53%) | |
| | ≥three drug therapy | 52 (28%) | 24 (21%) | 28 (40%) | |
| Surgical treatment | |||||
| | Medical and surgical | 99 (52%) | 65 (55%) | 34 (47%) | 0.3 |
| | Multiple valve procedures | 24 (24%) | 18 (15%) | 6 (8%) | 0.2 |
| Surgical treatment timing | |||||
| | Emergency (≤48 h) | 4 (4%) | 3 (5%) | 1 (3%) | 0.4 |
| | Urgent (>48 h and ≤7 days) | 12 (12%) | 9 (14%) | 3 (9%) | |
| | Elective (> 7 days) | 83 (84%) | 53 (81%) | 30 (88%) | |
| In-hospital mortality | 32 (17%) | 16 (14%) | 16 (23%) | 0.1 | |
| | Pre-operative | 20 (63%) | 11 (69%) | 9 (56%) | 0.8 |
| | Intra-operative | 2 (6%) | 1 (6%) | 1 (6%) | |
| Post-operative | 10 (31%) | 4 (25%) | 6 (38%) | ||
*Embolizations: Stroke (35, 19%); Non-Stroke (48, 25%) [Pulmonary (21), Cutaneous (5); Upper/lower extremities (3); Myocardial infarction (1); Splenic (12); Bone (6)].
Results of multivariable regression modeling of associations with in-hospital death
| Age in 10 y intervals | 1.26 (0.95-1.69) | 0.1 |
| Female sex | 0.60 (0.20-1.78) | 0.4 |
| PVE early recurrence | 0.88 (0.30-2.59) | 0.8 |
| PVE late recurrence | 2.12 (0.80-5.58) | 0.1 |
| Intravenous drug use | 0.60 (0.14-2.57) | 0.5 |
| Health care associated IE | 3.35 (1.27-8.78) | 0.01 |
| CoNS – associated IE | 0.50 (0.09-2.78) | 0.4 |
| 3.83 (0.95-15.44) | 0.058 | |
| Viridans group streptococci | 1.26 (0.33-4.77) | 0.7 |
| Others* | 1.98 (0.58-6.80) | 0.3 |
| Mitral valve involvement | 1.33 (0.53-3.30) | 0.5 |
| Complications** | 5.58 (1.79-17.31) | 0.003 |
| Surgery | 0.38 (0.16-0.94) | 0.04 |
CoNS, Coagulase-negative staphilococci; MSSA, Methicillin-sensitive Staphylococcus aureus; MRSA, Methicillin-resistant Staphylococcus aureus; PVE, prosthetic valve endocarditis.
*Others: Enterococcus spp, Fungi/Yeast, Gram-negative bacteria, polymicrobial.
**Complications: heart failure, renal failure, stroke, non stroke embolization, intracardiac abscess, septic shock, arrhythmias.